Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

Zoledronic acid in the management of metastatic bone disease

(2016) Thomas Polascik   Therapeutics and Clinical Risk Management

Biochemical-markers for the diagnosis of bone metastasis: A clinical review

(2011) Qian Huang et al.   Cancer Epidemiology

Metastasis and bone loss: Advancing treatment and prevention

(2010) Robert E. Coleman et al.   CANCER TREATMENT REVIEWS

Bone Turnover Markers as Predictors of Mortality Risk in Prostate Cancer Patients with Bone Metastases Following Treatment with Zoledronic Acid

(2010) Klaus Jung et al.   EUROPEAN UROLOGY

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

(2010) S. Vasikaran et al.   OSTEOPOROSIS INTERNATIONAL

Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid

(2010) Giannis Mountzios et al.   Translational Research

Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid

(2009) Michael Lein et al.   PROSTATE

Osteotropic cancers: From primary tumor to bone

(2008) Jeroen T. Buijs et al.   CANCER LETTERS